Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Pain. 2010 Dec;151(3):763–770. doi: 10.1016/j.pain.2010.09.009

Figure 5.

Figure 5

The enhancement of deltorphin exposure on μ-opioid receptor agonist effectiveness does not depend on the agonist used. (A-B) DAMGO (10 μg) alone did not affect PWLs to heat stimulation compared to vehicle-injected values. In contrast, co-administration of deltorphin (Delt, 30 μg) with DAMGO resulted in significantly elevated PWL measurements. (A) Time course. *p < 0.05 vs. vehicle. (B) Area under the curve (AUC). *p < 0.05 vs. vehicle and DAMGO alone groups. (C) DAMGO alone did not significantly inhibit K+-evoked CGRP release compared to vehicle pretreatment. When nerves were exposed to deltorphin prior to DAMGO pretreatment, robust inhibition was observed. *p < 0.05 vs. vehicle pretreatment. N = 4-7/group